Mederi Therapeutics, a US-based manufacturer and marketer of medical devices that deliver radiofrequency energy to treat disease states affecting the human digestive system, has released Stretta System for treatment of gastric reflux disease (GERD).
Mederi said that the Stretta Therapy delivers radiofrequency (RF) energy to the muscles of the Lower esophageal sphincter (LES), the valve that separates the stomach from the esophagus. Stretta tightens and restores the function of this valve, which in turn reduces or eliminates regurgitation and acid exposure to the esophagus, thus reducing a patient’s symptoms of GERD.
Stretta therapy is an outpatient (same day) minimally invasive procedure. After the procedure, patients can go home shortly and typically resume normal activities within several days. Stretta clinical studies show a 90% patient satisfaction score. Further, recent clinical studies have demonstrated symptom relief lasting at least 4 years.
Will Rutan, CEO of Mederi, said: “Up to 20% of the population does not respond to available medications for GERD. Others have failed to get relief from surgery. In these and other properly selected patients, Stretta offers an effective, minimally invasive alternative. GERD has a negative impact on sufferer’s quality of life. Stretta offers a much needed minimally invasive bridge between medications and invasive surgery.”